Aim is to present outcomes of BMMNCT for children with cerebral palsy (CP) and autism.
Bone marrow were harvested from anterior iliac crests.
After processing, 5ml of solution contain mononuclear cells were intrathecally infused through the space between L4 and L5.
From 2015-2019, three clinical trials have been carried out.
Clinical trial 1:
30 patients with CP related to oxygen deprivation received BMMNCT.
Significant changes were observed in the children's gross motor function and muscle spasticity, as evidenced by the GMFM-88 total score, scores for each of its domains, the GMFM-66 percentile and the muscle tone (P < 0.001).
Six months after the transplantations, the QOL scores of children with CP were markedly increased (P < 0.001) for all the domains, except for the domain of access to services.
Clinical trial 2:
25 patients with CP related to neonatal kernicterus underwent BMMNCT.
In this trial, we observed significant improvement in gross motor function and a significant decrease in muscle tone values.
Total score on the 88-item GMFM (GMFM-88), scores on each GMFM-88 domain, and the 66-item GMFM (GMFM-66) percentile were significantly enhanced at 6 months and 12 months after the first transplantation compared with the corresponding baseline measurements (p-values < 0.05). In addition, a significant reduction was observed in muscle tone score after the transplantations (p-value < 0.05).
Clinical trial 3:
30 patients with autism received BMMNCT. There were no severe adverse events associated with transplantation.
After transplantation 18 months, social communication, language, daily skills improved significantly.
Repetitive behaviors, hyperactive manifestation significant decreased.
Severity of autism reduced significantly: CARS score from 49.9 to 45.2, ADOS scores from 10 to 8.
Adaptive capacity increased with change of Vineland scores from 52.4 to 60.4
Autologous BMMCT is safe and effective for children with CP related to oxygen deprivation, to neonatal kernicterus, and autism.